On this page
Key takeaways
• Fisetin was identified in a 2018 Mayo Clinic flavonoid screen as the most potent of ten tested natural compounds at selectively killing senescent cells while sparing healthy dividing cells (1).
• The mechanism is a hit-and-run interference with senescent cell anti-apoptotic pathways (SCAPs — BCL-2, BCL-xL, PI3K/AKT), pushing senescent cells past their apoptotic threshold (2,15).
• In vivo mouse evidence includes reduced senescent-cell burden, reduced SASP markers, and modest lifespan extension in aged mice (1). Independent 2025 replication showed fisetin equivalent to genetic clearance for muscle function (6).
• Six human trials use the same dosing protocol — 20 mg/kg × 2 days, every 28 days — the hit-and-run pattern (7,8,9,10,11,12).
• No peer-reviewed human RCT has yet reported a positive senolytic endpoint for oral fisetin. AFFIRM has been running since 2018 (7). COVID-FIS posted preliminary results in August 2025 (8).
• The translational bottleneck is bioavailability. Unformulated fisetin achieves plasma concentrations 30–150-fold below the in vitro senolytic window (17).
Quick answer
Fisetin is a senolytic — a class of compounds that selectively kill senescent cells. This identity is well established in mouse tissue and human cell cultures. Whether oral fisetin at supplement doses produces the same effect in a living human adult is currently unknown: every published human trial uses an intermittent pulsed protocol (20 mg/kg × 2 days, every 28 days) that most commercial products do not follow, and no peer-reviewed randomised trial has yet reported a senolytic endpoint in humans. This article walks through the founding biology, the mechanism, the six ongoing or completed human trials, and the honest translational picture. For the complete clinical guide, see our pillar article on fisetin.
What senolytic means — the biology in 90 seconds
Cellular senescence is a stress response. When a cell suffers DNA damage, telomere shortening, or oncogenic activation that it cannot repair, it exits the cell cycle permanently. This is a good thing in principle — a cell that stops dividing cannot become cancerous. But senescent cells do not die on schedule. They accumulate in tissue as we age, and they secrete a cocktail of pro-inflammatory factors called the Senescence-Associated Secretory Phenotype (SASP) — IL-6, TNF-α, IL-1β, CXCL12, and matrix metalloproteinases. The SASP damages surrounding tissue, drives chronic inflammation, and contributes to age-related disease. Genetically clearing senescent cells in mice, using the INK-ATTAC construct developed at Mayo Clinic, extends median lifespan by roughly 25% and reduces multiple age-related pathologies (3).
A senolytic is a small molecule that mimics this genetic clearance — it selectively kills senescent cells while sparing healthy proliferating cells. The founding senolytic protocol, developed by James Kirkland and colleagues at Mayo Clinic, is the combination of dasatinib (a leukaemia drug) plus quercetin (a flavonoid). In 2018, the same group screened ten flavonoids for senolytic activity and reported that fisetin was the most potent — hence its subsequent adoption as the natural senolytic candidate of choice (1,3).
The founding paper — Yousefzadeh 2018
Yousefzadeh and colleagues (EBioMedicine, 2018) is the load-bearing paper for the fisetin senolytic story (1). The study has four principal findings that together define the modern fisetin case.
1. In vitro: fisetin selectively kills senescent cells
Senescent mouse embryonic fibroblasts, senescent IMR90 human lung fibroblasts, and senescent HUVEC endothelial cells all showed selective apoptosis when treated with 5 μM fisetin. Healthy dividing cells of the same types were spared at this concentration. Above roughly 20–100 μM, selectivity was lost and fisetin’s effects extended to proliferating cells — this is the senolytic window that defines the therapeutic index (2).
2. In progeroid mice: fisetin reduces senescent-cell burden
Ercc1⁻/Δ mice, a progeria model, showed reduced senescent-cell markers (p16, p21, SA-β-gal) across multiple tissues after a five-day gavage of fisetin at 100 mg/kg. Downstream inflammatory markers (IL-6, TNF-α, IL-1β) were also reduced.
3. In wild-type old mice: fisetin reduces senescent cells and extends lifespan
Wild-type mice started on fisetin-supplemented chow (500 mg/kg in food) at 85 weeks of age lived longer than controls by median lifespan and had reduced age-related histopathology. This is the mouse-lifespan finding that anchors marketing claims about "healthy aging."
4. In human adipose tissue explants: fisetin translates ex vivo
Ex vivo treatment of human adipose tissue explants with fisetin reduced senescent-cell markers in a subset of cells, providing the first evidence that fisetin’s senolytic activity extends to human tissue outside the mouse.
These four findings together made a strong preclinical and translational case. The paper has been cited more than 1,600 times as of mid-2026. What it did not establish — and what the field has spent eight years trying to establish — is that oral fisetin at achievable human doses produces the same senolytic effect in a living human being.
The mechanism — how fisetin targets senescent cells specifically
Senescent cells survive by upregulating pro-survival pathways collectively called SCAPs — Senescent Cell Anti-Apoptotic Pathways. These include BCL-2 and BCL-xL (mitochondrial anti-apoptotic proteins), PI3K/AKT signalling, HIF-1α, and several tyrosine kinases. The pharmaceutical senolytic ABT-263 (navitoclax) targets BCL-xL specifically. Dasatinib targets tyrosine kinases. Quercetin has multiple targets including PI3K and BCL-xL.
Fisetin appears to interfere with several SCAPs simultaneously — a promiscuous mechanism that may explain its potency in cell-culture screens (2,15). It has documented activity at BCL-xL, at PI3K/AKT, and at Nrf2-regulated antioxidant pathways. The lack of a single dominant target makes fisetin harder to characterise pharmacologically than a targeted senolytic like navitoclax, but it may also give it broader selectivity across different senescent-cell types — the Yousefzadeh 2018 paper demonstrated activity in mouse and human cells of multiple lineages, which is unusual for senolytic screening.
Selectivity depends on concentration. At the low end of the senolytic window (roughly 1 μM), fisetin kills only senescent cells. As concentration rises above roughly 20 μM, healthy proliferating cells begin to show reduced viability too. This is why the trial protocols use short pulses of high concentration rather than continuous low dosing — the goal is to briefly hit the senolytic window in tissue, then let it fall away.
The hit-and-run principle — why intermittent dosing
This is the single most important pharmacological principle in the fisetin literature, and the reason every published human trial uses a pulsed protocol rather than daily dosing.
Senescent cells regenerate slowly. Once a pulse of senolytic drug has cleared them from a tissue, weeks to months pass before the population rebuilds. Continuous senolytic exposure is therefore not necessary — indeed, it may be counterproductive, both because it risks off-target effects on healthy cells and because it may down-regulate the responsiveness of senescent cells to repeated pharmacological pressure. The founding senolytic protocol of dasatinib plus quercetin was designed on this principle — three consecutive days per month, then 25 days off (3). Fisetin adopted the same architecture — 20 mg/kg × 2 days, then 28 days off (7,8).
This is why the daily-capsule format on most commercial fisetin products does not match any published efficacy protocol. It is not a matter of manufacturer bad faith — daily capsules are commercially convenient and low-dose flavonoid intake has independent pharmacological interest. But readers should understand that the senolytic story specifically is a hit-and-run story. Our dedicated pulse dosing article walks through the exact protocol and how to translate it into a practical schedule.
The human trial pipeline — six protocols, one dose
Six human trials have used or are using oral fisetin as a senolytic. All use variations of the same 20 mg/kg × 2 days pulsed protocol. The list below is as of mid-2026.
|
Trial (NCT) |
Indication |
Status |
Reference |
|
AFFIRM (NCT03430037) |
Frailty in post-menopausal women |
Running since 2018; not yet reported |
Mayo Clinic (7) |
|
COVID-FIS (NCT04537299) |
COVID-19 in nursing home residents |
Topline results August 2025; manuscript pending |
|
|
COVFIS-HOME (NCT04771611) |
Community-dwelling adults with COVID-19 |
Recruitment complete; results pending |
Multi-centre (9) |
|
Cartilage Trial (NCT04210986) |
Cartilage degeneration in osteoarthritis |
Recruiting |
Mayo Clinic (10) |
|
PROFFi (NCT06113016) |
Frailty in breast cancer survivors |
Recruiting |
UCLA (11) |
|
Fisetin HIGH (NCT06431932) |
Healthy volunteers and multimorbid older adults |
Recruiting since March 2026 |
Hvidovre Univ (12) |
The AFFIRM trial is the load-bearing readout for the field. It is a Phase 2 double-blind randomised placebo-controlled trial with the Mayo Clinic pulsed protocol as the intervention, and reduction of frailty, inflammatory markers, and — critically — senescent-cell biomarkers in adipose tissue as the endpoints. It has been running for eight years. When it publishes, this article and the entire cluster will be revised comprehensively. Sundeep Khosla’s 2025 GeroScience review on translating senolytics from mice to humans acknowledges this readout gap explicitly (14).
The 2025 preclinical data — Murray et al.
Murray and colleagues (Aging Cell, 2025) is the most consequential preclinical fisetin paper since Yousefzadeh 2018 (6). The design compared four interventions in 24-month-old mice: vehicle control, intermittent fisetin at the mouse equivalent of the human pulsed protocol, INK-ATTAC genetic clearance of p16-positive cells, and ABT-263 (the pharmaceutical BCL-xL inhibitor). Fisetin preserved grip strength, gait speed, and muscle fibre integrity to a degree statistically indistinguishable from INK-ATTAC and ABT-263. Reduced senescent-cell markers in skeletal muscle tissue supported the mechanistic case.
This is a striking result because head-to-head equivalence between a natural flavonoid and gold-standard senolytic interventions is rarely reported and rarely favourable for the natural compound. It has been widely cited as the strongest recent preclinical evidence supporting fisetin’s legitimacy as a senolytic. It does not, however, close the human translational gap — that remains the AFFIRM trial’s job to close.
What senolytic vs senomorphic means — a distinction worth understanding
Senolytic and senomorphic are two related but distinct pharmacological categories in the geroscience literature.
A senolytic kills senescent cells outright — it induces apoptosis in cells that had adopted a persistent senescent phenotype. This is the effect Yousefzadeh 2018 demonstrated in cell culture and in mouse tissue. It is the effect the human trials are testing.
A senomorphic does not kill senescent cells — it silences their inflammatory secretome, suppressing the SASP without removing the cells themselves. Rapamycin and metformin have senomorphic activity. Some fisetin formulations may too: a 2024 cell-culture study of liposome-encapsulated fisetin found that the liposomal formulation lost senolytic activity and instead reduced IL-6 and IL-8 secretion from senescent cells — a shift from senolytic to senomorphic. This has consequences for how liposomal fisetin should be interpreted, discussed in our dedicated liposomal fisetin article.
What we still don't know
• Whether oral fisetin at trial doses reduces senescent-cell burden in humans in any tissue. This is the central unanswered question. AFFIRM and Fisetin HIGH will begin to answer it.
• Whether the effect on adipose tissue senolysis extends to musculoskeletal, cardiovascular, and neural tissue in humans. Murray 2025 provides preclinical support for muscle (6); humans remain untested.
• How long the senolytic effect persists after each pulse. The mouse work suggests weeks to months; the human durability is speculative.
• Whether repeated pulses over years produce cumulative benefit or hit a ceiling as the resistant senescent-cell subset expands. This is a several-year question.
• Whether fisetin’s senolytic activity meaningfully depends on the geraldol metabolite in vivo. Fisetin is rapidly methylated after absorption, and some of the biological activity may belong to geraldol (17).
• Whether the 2024 review by Niedernhofer and Robbins — the most balanced academic summary — accurately predicts the AFFIRM outcome (16). They flag bioavailability and rapid metabolism as barriers to clinical translation.
Bottom line
Fisetin is the most credible natural senolytic candidate in the longevity literature and the least clinically proven. The preclinical case is genuinely strong — a specific mechanism, selective apoptosis in the senolytic concentration window, effect sizes in mouse tissue that rival gold-standard interventions, ex vivo activity in human tissue explants. The clinical case is a promise: six trials in progress, none yet fully reported, all using a hit-and-run pulsed dosing protocol that most commercial products do not follow. Anyone taking fisetin as a senolytic today is doing so on the strength of the preclinical case and a bet on translation. That is a legitimate position; it is not the same thing as taking a supplement with proven senolytic effect in humans. The AFFIRM and Hvidovre trial readouts, when they arrive, will materially reshape this article.
Frequently asked questions
Is fisetin actually a senolytic in humans?
Unknown, based on published peer-reviewed randomised trials. The mouse and cell-culture evidence is strong. Human evidence is pending. AFFIRM and Fisetin HIGH will be the first randomised human tests to report.
What is the difference between fisetin and dasatinib plus quercetin?
Dasatinib is a prescription tyrosine kinase inhibitor used for chronic myeloid leukaemia. Quercetin is a flavonoid similar to fisetin. Together they were the founding senolytic combination (3,4,5). Fisetin was developed as a natural single-agent alternative — more potent than quercetin alone in cell-culture screens, and not requiring a prescription drug. Human trial data are more mature for D+Q; preclinical data are stronger for fisetin.
Should I take fisetin daily or in pulses?
The senolytic biology and every published human trial protocol argue for pulses (20 mg/kg × 2 days, every 28 days). Daily dosing at typical capsule strengths matches no efficacy protocol. Our dedicated pulse dosing article walks through the practical schedule.
Will taking more fisetin clear more senescent cells?
Above the senolytic concentration window (roughly 20 μM in cell culture), selectivity is lost and healthy cells become affected. "More is better" is not the correct model for senolytic dosing. The pulsed protocol is designed to hit the window briefly, not to sustain it.
Does fisetin work in combination with quercetin?
Preclinically, some studies have used fisetin plus quercetin together with additive or synergistic effects, but no published human RCT has tested the specific combination. Our fisetin vs quercetin article covers both the comparison and the stacking question.
When will we know if fisetin actually works?
The AFFIRM readout is the load-bearing publication. It has been overdue since roughly 2021. When it publishes — and when Fisetin HIGH and PROFFi follow within 24 to 36 months — the field will have its first randomised, controlled test of the senolytic hypothesis in humans with oral fisetin. Until then, translation from mice to humans is a hypothesis worth participating in but not a documented benefit.
References
1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
2. Zhu Y, Doornebal EJ, Pirtskhalava T, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY). 2017;9(3):955-963. https://pubmed.ncbi.nlm.nih.gov/28273655/
3. Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-1256. https://pubmed.ncbi.nlm.nih.gov/29988130/
4. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. https://pubmed.ncbi.nlm.nih.gov/30616998/
5. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456. https://pubmed.ncbi.nlm.nih.gov/31542391/
6. Murray KO, Mahoney SA, Venturini S, et al. Intermittent supplementation with fisetin improves physical function and decreases cellular senescence in skeletal muscle with aging. Aging Cell. 2025;24:e70114. https://doi.org/10.1111/acel.70114
7. AFFIRM: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (NCT03430037). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03430037
8. COVID-FIS: Phase 2 Placebo-Controlled Pilot Study of Fisetin in Older Adults in Nursing Homes (NCT04537299). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04537299
9. COVFIS-HOME: Home-Based Study to Assess Fisetin in Community-Dwelling Adults With COVID-19 (NCT04771611). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04771611
10. A Trial of Fisetin to Treat Cartilage Degeneration in Osteoarthritis (NCT04210986). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04210986
11. PROFFi: Prevention of Frailty with Fisetin and Exercise in Breast Cancer Survivors (NCT06113016). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06113016
12. Pilot Trial of Fisetin in Healthy Volunteers and Older Patients with Multimorbidity — Fisetin HIGH (NCT06431932). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06431932
13. Verdoorn BP, Evans TK, Hanson GJ, et al. Fisetin for COVID-19 in skilled nursing facilities: senolytic trials in the COVID era. J Am Geriatr Soc. 2021;69(11):3023-3033. https://pmc.ncbi.nlm.nih.gov/articles/PMC8447437/
14. Khosla S. Translating senolytics from mice to humans. GeroScience. 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12759346/
15. Elsallabi O, Patruno A, Pesce M, et al. Fisetin as a senotherapeutic agent: biopharmaceutical properties and crosstalk between cell senescence and neuroprotection. Molecules. 2022;27(3):738. https://pmc.ncbi.nlm.nih.gov/articles/PMC8838024/
16. Niedernhofer LJ, Robbins PD. Fisetin as a senotherapeutic agent: evidence and perspectives for age-related diseases. Mech Ageing Dev. 2024;220:111995. https://doi.org/10.1016/j.mad.2024.111995
17. Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals. J Nutr Sci. 2022;11:e74. https://doi.org/10.1017/jns.2022.72